|
1
|
Doroshow DB and Herbst RS: Treatment of
advanced non-small cell lung Cancer in 2018. JAMA Oncol. 4:569–570.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohe Y, Ohashi Y, Kubota K, Tamura T,
Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y and Fukuoka
M: Randomized phase III study of cisplatin plus irinotecan versus
carboplatin plus paclitaxel, cisplatin plus gemcitabine, and
cisplatin plus vinorelbine for advanced non-small-cell lung cancer:
Four-Arm cooperative study in Japan. Ann Oncol. 18:317–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fossella F, Pereira JR, von Pawel J,
Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna
A, Fidias P, et al: Randomized, multinational, phase III study of
docetaxel plus platinum combinations versus vinorelbine plus
cisplatin for advanced non-small-cell lung cancer: The TAX 326
study group. J Clin Oncol. 21:3016–3024. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scagliotti GV, Parikh P, von Pawel J,
Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U,
Digumarti R, Zukin M, et al: Phase III study comparing cisplatin
plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-I
patients with advanced-stage non-small-cell lung cancer. J Clin
Oncol. 26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rodrigues-Pereira J, Kim JH, Magallanes M,
Lee DH, Wang J, Ganju V, Martinez-Barrera L, Barraclough H, van
Kooten M and Orlando M: A randomized phase 3 trial comparing
pemetrexed/carboplatin and docetaxel/carboplatin as first-line
treatment for advanced, nonsquamous non-small cell lung cancer. J
Thorac Oncol. 6:1907–1914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Scagliotti GV, Gridelli C, de Marinis F,
Thomas M, Dediu M, Pujol JL, Manegold C, San Antonio B, Peterson
PM, John W, et al: Efficacy and safety of maintenance pemetrexed in
patients with advanced nonsquamous non-small cell lung cancer
following pemetrexed plus cisplatin induction treatment: A
cross-trial comparison of two phase III trials. Lung Cancer.
85:408–414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harboring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicenter, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicenter, open-label, randomised multicenter phase 3
trial. Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa
K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, et al: Dacomitinib
versus gefitinib as first-line treatment for patients with
EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A,
randomised open-label, phase 3 trial. Lancet Oncol. 18:1454–1466.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hong S, Gao F, Fu S, Wang Y, Fang W, Huang
Y and Zhang L: Concomitant genetic alterations with response to
treatment and epidermal growth factor receptor tyrosine kinase
inhibitors in patients with EGFR-mutant advanced non-small CELL
lung cancer. JAMA Oncol. 4:739–742. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ, et al:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Janne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L,
Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA,
et al: Osimertinib in patients with T790M mutation-positive,
advanced non-small cell lung cancer: Long-Term follow-up from a
pooled analysis of 2 phase 2 studies. Cancer. 15:892–901. 2018.
|
|
18
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et
al: Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung
cancer. N Engl J Med. 376:629–640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang Z, Yang N, Ou Q, Xiang Y, Jiang T, Wu
X, Bao H, Tong X, Wang X, Shao YW, et al: Investigating novel
resistance mechanisms to third-generation EGFR tyrosine kinase
inhibitor osimertinib in non-small cell lung cancer patients. Clin
Cancer Res. 24:3097–3107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bolger AM, Lohse M and Usadel B:
Trimmomatic: A flexible trimmer for Illumina sequence data.
Bioinformatics. 30:2114–2120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koboldt DC, Zhang Q, Larson DE, Shen D,
McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK:
VarScan 2: Somatic mutation and copy number alteration discovery in
cancer by exome sequencing. Genome Res. 22:568–576. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sherry ST, Ward MH, Kholodov M, Baker J,
Phan L, Smigielski EM and Sirotkin K: Dbsnp: The NCBI database of
genetic variation. Nucleic Acids Res. 29:308–311. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang K, Li M and Hakonarson H: ANNOVAR:
Functional annotation of genetic variants from high-throughput
sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Newman AM, Bratman SV, Stehr H, Lee LJ,
Liu CL, Diehn M and Alizadeh AA: FACTERA: A practical method for
the discovery of genomic rearrangements at breakpoint resolution.
Bioinformatics. 30:3390–3393. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Moone M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zubrod CG, Schleiderman M, Frei S,
Brindley C, Gold GL, Shnider B, Oviedo R, Gorman J, Jones Jr R,
Jonsson U, et al: Appraisal of methods for the study of
chemotherapy of cancer in man: Comparative therapeutic trial of
nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis.
11:7–33. 1960. View Article : Google Scholar
|
|
27
|
Fukuoka M, Wu YL, Thongprasert S,
Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu
DT, Saijo N, et al: Biomarker analyses and final overall survival
results from a phase III, randomized, open-label, first-line study
of gefitinib versus carboplatin/paclitaxel in clinically selected
patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wu M, Zhao J, Song SW, Zhuo M, Wang X, Bai
H, Wang S, Yang L, An T, Zhang Y, et al: EGFR mutations are
associated with prognosis but not with the response to front-line
chemotherapy in the Chinese patients with advanced non-small cell
lung cancer. Lung Cancer. 67:343–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marabese M, Ganzinelli M, Garassino MC,
Shepherd FA, Piva S, Caiola E, Macerelli M, Bettini A, Lauricella
C, Floriani I, et al: KRAS mutations affect prognosis of
non-small-cell lung cancer patients treated with first-line
platinum containing chemotherap. Oncotarget. 6:34014–34022. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Macerelli M, Caramella C, Faivre L, Besse
B, Planchard D, Polo V, Ngo Camus M, Celebic A, Koubi-Pick V,
Lacroix L, et al: Does KRAS mutational status predict
chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Lung Cancer. 83:383–388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cardarella S, Ogino A, Nishino M, Butaney
M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE and Jänne PA:
Clinical, pathologic, and biologic features associated with BRAF
mutations in non-small cell lung cancer. Clin Cancer Res.
19:4532–4540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Van Laar RK: Genomic signatures for
predicting survival and adjuvant chemotherapy benefit in patients
with non-small-cell lung cancer. BMC Med Genomics. 5:302012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu CQ, Ding K, Strumpf D, Weir BA,
Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, et
al: Prognostic and predictive gene signature for adjuvant
chemotherapy in resected non-small-cell lung cancer. J Clin Oncol.
28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Booth L, Poklepovic A and Dent P: Not the
comfy chair! Cancer drugs that act against multiple active sites.
Expert Opin Ther Targets. 23:893–901. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mun H, Lee SH, Lee CH, Jo SY, Oh JH, Lee
A, Lee B, Jang SJ and Suh YA: Taxotere induces dephosphorylation of
MET in patient-derived tumor models. Anticancer Res. 40:109–119.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang Z, Cheng Y, An T, Gao H, Wang K, Zhou
Q, Hu Y, Song Y, Ding C, Peng F, et al: Detection of EGFR mutations
in plasma circulating tumour DNA as a selection criterion for
first-line gefitinib treatment in patients with advanced lung
adenocarcinoma (BENEFIT): A phase 2, single-arm, multicenter
clinical trial. Lancet Respir Med. 6:681–690. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen M, Xu Y, Zhao J, Zhong W, Zhang L, Bi
Y and Wang M: Concurrent driver gene mutations as negative
predictive factors in epidermal growth factor receptor-positive
non-small cell lung cancer. Ebiomedicine. 42:304–310. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang JCH, Ahn MJ, Kim DW, Ramalingam SS,
Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, et al:
Osimertinib in pretreated T790M-positive advanced non-small-cell
lung cancer: AURA study phase II extension component. J Clin Oncol.
35:1288–1296. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Goss G, Tsai CM, Shepherd FA, Bazhenova L,
Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, et al:
Osimertinib for pretreated EGFR Thr790Met-positive advanced
non-small-cell lung cancer (AURA2): A multicenter, open-label,
single-arm, phase 2 study. Lancet Oncol. 17:1643–1652. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marusyk A, Almendro V and Polyak K:
Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev
Cancer. 12:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Almendro V, Marusyk A and Polyak K:
Cellular heterogeneity and molecular evolution in cancer. Ann Rev
Pathol. 8:277–302. 2013. View Article : Google Scholar
|
